EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Biological Evaluation of Cleavable Linkers in Exatecan-Based Antibody–Drug Conjugates: A Comparative Study of DXd and Exo-Linker Platforms

Tomohiro Watanabe, Yusuke Iwai, Natsuki Shikida, Jason T Stofleth iD, Tomohiro Fujii, Takuya Seki, Kazutaka Shimbo, Yutaka Matsuda iD

ACS Omega · 02.09.2025 · 10 (34) · 38696-38702

DOI: 10.1021/acsomega.5c03755 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Omega, online erschienen am 19.08.2025. Verfasst von Tomohiro Watanabe und 7 weiteren Autor:innen. Beteiligte Einrichtung: Ajinomoto Co., Inc., 1-1, Suzuki-Cho, Kawasaki-Ku, Kawasaki-Shi, Kanagawa 210-8681, Japan. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapies that combine the specificity of monoclonal antibodies with the cytotoxicity of potent drug payloads. This study presents the development and evaluation of a novel linker platform designed to enhance ADC stability and pharmacokinetics by addressing the limitations associated with traditional cleavable linkers. Using trastuzumab conjugated with a payload linker consisting of this platform and exo-EVC-Exatecan (APL-1082), we examined key parameters, including in vivo efficacy and pharmacokinetic profiles in rat models, to directly compare it with the clinically validated trastuzumab-deruxtecan (T-DXd, Enhertu). The resulting ADC demonstrated superior stability and maintained drug-to-antibody ratios (DAR) with reduced aggregation and hydrophobicity compared to T-DXd, suggesting an improved pharmacokinetic profile. Additionally, combining APL-1082 with AJICAP site-specific conjugation technology enabled the production of high-DAR ADCs, achieving a DAR of 10 with promising homogeneity and physicochemical properties. Collectively, these findings underscore the potential of this novel linker as a versatile platform for next-generation ADCs, offering enhanced stability, efficacy, and expanded therapeutic possibilities.

Autor:innen und Institutionen

  • Ajinomoto Co., Inc., 1-1, Suzuki-Cho, Kawasaki-Ku, Kawasaki-Shi, Kanagawa 210-8681, Japan.
  • Ajinomoto Bio-Pharma Services, 11040 Roselle Street, San Diego, California 92121, United States.

ORCID-Profile: Jason T Stofleth, Yutaka Matsuda

Zitieren

APA

Watanabe, T., Iwai, Y., Shikida, N., Stofleth, J. T., Fujii, T., Seki, T., Shimbo, K., & Matsuda, Y. (2025). Biological Evaluation of Cleavable Linkers in Exatecan-Based Antibody–Drug Conjugates: A Comparative Study of DXd and Exo-Linker Platforms. ACS Omega, 10(34), 38696-38702. https://doi.org/10.1021/acsomega.5c03755

Vancouver

Watanabe T, Iwai Y, Shikida N, Stofleth JT, Fujii T, Seki T, et al. Biological Evaluation of Cleavable Linkers in Exatecan-Based Antibody–Drug Conjugates: A Comparative Study of DXd and Exo-Linker Platforms. ACS Omega. 2025;10(34):38696-38702. doi:10.1021/acsomega.5c03755

BibTeX
@article{Watanabe2025,
  author = {Watanabe, Tomohiro and Iwai, Yusuke and Shikida, Natsuki and Stofleth, Jason T and Fujii, Tomohiro and Seki, Takuya and Shimbo, Kazutaka and Matsuda, Yutaka},
  title = {Biological Evaluation of Cleavable Linkers in Exatecan-Based Antibody–Drug Conjugates: A Comparative Study of DXd and Exo-Linker Platforms},
  journal = {ACS Omega},
  year = {2025},
  volume = {10},
  number = {34},
  pages = {38696--38702},
  doi = {10.1021/acsomega.5c03755}
}
Kostenlos starten →